… pDC functionality, as pDCs from patients with ovarian cancer were compared in blood, in …
patients with lung cancer, finding no significant difference when compared with cancer patients …

… dendritic cells have been used in clinical trials as cellular mediators for therapeutic
vaccination of patients with cancer… of dendritic cell vaccination with other cancer therapies. …

… -phase clinical trials of dendritic cells for the treatment of cancer. These … This paper reviews
the biology of dendritic cells and their … patients of a vaccine with peptide-pulsed dendritic cells …

… of immune cell differentiation and function makes this unique environment even more intricate
and variable. Dendritic cells (DCs) represent a special group of cells that display different …

… -driven immunosuppressive leukocyte infiltrates, mainly myeloid-derived suppressor cells,
tumor-associated macrophages, and immature dendritic cells (DCs). In addition, many tumors …

… have been shown to require nitric oxide synthase-2 (NOS2/iNOS), which is abundant in,
for example, ascites from ovarian cancer patients [70]. The presence of PGE 2 during in vitro …

… in a manner that rendersthem immunogenic in patients with cancer. However, recent insights
into therole of dendritic cells (DC) as the pivotal antigen-presenting cells (APC) thatinitiate …

… 7 Improved stimulation of influenza virus-specific CTLs by breast cancer patient DCs … when
T cells from patients were stimulated … capacity of the T cells from cancer patients, we tested …

Dendritic cells (DC) represent potent APCs that are capable of generating tumor-specific
immunity. We performed a pilot clinical trial using Ag-pulsed DC as a tumor vaccine. Twenty-…

… Surgical removal of the tumor had a great impact on the presence of immature cells in
cancer patients. We compared the proportion of immature cells in five cancer patients. All …